Performance in the Diversified segment improved primarily due to better net pricing realized during the fourth quarter.The acquisition of Shibo in China and DURECT's larsucosterol platform represent a strategic shift toward proactive business development to enhance long-term growth.Management attributed the 10% full-year adjusted EBITDA growth to portfolio optimization and increased operating leverage without the benefit of major acquisitions.International segment growth was supported by leading market posi ...